Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
SOTYKTU (Bristol-Myers Squibb Australia Pty Ltd)
Product name
SOTYKTU
Date registered
Evaluation commenced
Decision date
Approval time
222 (255 working days)
Active ingredients
deucravacitinib
Registration type
NCE/NBE
Indication
SOTYKTU is indicated for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.